CheemaH., BargmanJ.M.Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?Perit Dial Int2013; 33: 349–52.
2.
KoomenG.C., BetjesM.G., ZemelD., KredietR.T., HoekF.J.Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis.Perit Dial Int1994; 14: 132–6.
3.
ZeillemakerA.M., VerbrughH.A., Hoynck van PapendrechtA.A., LeguitP.CA 125 secretion by peritoneal mesothelial cells.J Clin Pathol1994; 47: 263–5.
4.
VisserC.E., Brouwer-SteenbergenJ.J., BetjesM.G., KoomenG.C., BeelenR.H., KredietR.T.Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.Nephrol Dial Transplant1995; 10: 64–9.
5.
BreborowiczA., BreborowiczM., PydaM., PołubinskaA., OreopoulosD.Limitations of CA125 as an index of peritoneal mesothelial cell mass.nephron Clin Pract2005; 100: c46–51.
6.
SanusiA.A., ZweersM.M., WeeningJ.J., de WaartDr, StruijkD.G., KredietR.T.Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis.Perit Dial Int2001; 21: 495–500.
7.
PannekeetM.M., KoomenG.C., StruijkD.G., KredietR.T.Dialysate CA125 in stable CAPD patients: no relation with transport parameters.Clin Nephrol1995; 44: 248–54.
8.
LaiK.N., LaiK.B., SzetoC.C., HoK.K., PoonP., LamC.W.Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters.Am J Kidney Dis1997; 29: 699–705.
9.
CoesterA.M., HuttenH., ZweersM.M., de WaartDr, KredietR.T.The relationship between effluent potassium due to cellular release, free water transport and CA125 in peritoneal dialysis patients.NDT Plus2008; 1(Suppl 4): iv41–5.
10.
van EschS., ZweersM.M., JansenM.A., de WaartDr, van ManenJ.G., KredietR.T.Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.Perit Dial Int2004; 24: 554–61.
11.
PannekeetM.M., ZemelD., KoomenG.C., StruijkD.G., KredietR.T.Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD.Perit Dial Int1995; 15: 217–25.
12.
BetjesM.G., TukC.W., VisserC.E., ZemelD., KredietR.T., AriszL.Analysis of the peritoneal cellular immune system during CAPD shortly before a clinical peritonitis.Nephrol Dial Transplant1994; 9: 684–92.
13.
HekkingL.H., ZareieM., DriesprongB.A., FaictD., WeltenA.G., de GreeuwI.Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution.J Am Soc Nephrol2001; 12: 2775–86.
14.
KredietR.T., ZweersM.M., van WestrhenenR., ZegwaardA., StruijkD.G.Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?NDT Plus2008; 1(Suppl 4): iv56–62.
15.
ShimizuH., IshibashiY., KumagaiT., KanameS., FujitaT., SaiK.Long-term effect of peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration on peritoneum: a case report.Perit Dial Int2007; 27: 92–4.
16.
KawanishiK., HondaK., TsukadaM., OdaH., NittaK.Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.Perit Dial Int2013; 33: 242–51.
